111 related articles for article (PubMed ID: 32510792)
1. An open-label dose escalation study evaluating tolerability and safety of a single 5-days course of temozolomide in dogs with advanced cancer.
Marconato L; Rohrer Bley C; Leone VF; Finotello R
Vet Comp Oncol; 2020 Dec; 18(4):838-842. PubMed ID: 32510792
[TBL] [Abstract][Full Text] [Related]
2. An open-label phase 1 dose-escalation clinical trial of a single intravenous administration of gemcitabine in dogs with advanced solid tumors.
Marconato L; Finotello R; Bonfanti U; Dacasto M; Beatrice L; Pizzoni S; Leone VF; Balestra G; Furlanello T; Rohrer Bley C; Aresu L
J Vet Intern Med; 2015; 29(2):620-5. PubMed ID: 25818216
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Brada M; Judson I; Beale P; Moore S; Reidenberg P; Statkevich P; Dugan M; Batra V; Cutler D
Br J Cancer; 1999 Nov; 81(6):1022-30. PubMed ID: 10576660
[TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
6. Phase I study to determine the maximal tolerated dose and dose-limiting toxicities of orally administered idarubicin in dogs with lymphoma.
Vail DM; Husbands BD; Kamerling SG; Simpson H; Kurzman ID; McDonnell A
J Vet Intern Med; 2012; 26(3):608-13. PubMed ID: 22404399
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
[TBL] [Abstract][Full Text] [Related]
9. Dose-Escalation and Pharmacokinetic Study Following a Single Dose of Oxaliplatin in Cancer-Bearing Dogs.
Klahn S; Dervisis N; Gustafson DL; Abbott J
J Am Anim Hosp Assoc; 2020; 56(4):206-214. PubMed ID: 32412339
[No Abstract] [Full Text] [Related]
10. An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs.
Fiocchi SC; Selting KA; Rosenberg MP; Kolli P; Lenaz G; Henry C
J Vet Intern Med; 2011; 25(4):897-902. PubMed ID: 21736623
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 dose escalation trial of TAS-102 (trifluridine/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors.
Uboha NV; Lubner SJ; LoConte NK; Mulkerin DL; Eickhoff JC; Deming DA
Invest New Drugs; 2020 Oct; 38(5):1520-1525. PubMed ID: 32253554
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability and pharmacokinetic properties of the novel triazene TriN 2755 in tumour bearing dogs - a phase I study
Athanasiadi I; Geigy C; Hilger RA; Meier V; Rohrer Bley C
Vet Comp Oncol; 2017 Mar; 15(1):94-104. PubMed ID: 25689225
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB
Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose escalation of single-agent vinblastine in dogs.
Bailey DB; Rassnick KM; Kristal O; Chretin JD; Balkman CE
J Vet Intern Med; 2008; 22(6):1397-402. PubMed ID: 19000250
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs.
Axiak SM; Selting KA; Decedue CJ; Henry CJ; Tate D; Howell J; Bilof KJ; Kim DY
Int J Nanomedicine; 2011; 6():2205-12. PubMed ID: 22072863
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy.
Chiesa S; Hohaus S; Falcinelli L; D'Alò F; Martelli MF; Manfrida S; Beghella Bartoli F; Colosimo C; Valentini V; Aristei C; Balducci M
Ann Hematol; 2020 Oct; 99(10):2367-2375. PubMed ID: 32816079
[TBL] [Abstract][Full Text] [Related]
19. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Larkin JM; Hughes SA; Beirne DA; Patel PM; Gibbens IM; Bate SC; Thomas K; Eisen TG; Gore ME
Br J Cancer; 2007 Jan; 96(1):44-8. PubMed ID: 17146474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]